This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Desferrioxamine mesylate

Authoring team

  • desferrioxamine mesylate is used in the treatment of acute iron poisoning (commonest in children and generally accidental). Desferrioxamine chelates iron and intensive therapy with desferrioxamine increases survival of those with acute iron poisoning
  • desferrioxamine may also be used in the treatment of other conditions where severe tissue iron overload may occur e.g. aplastic and other refractory anaemias - in these cases iron overload mainly occurs secondary to repeated blood transfusions. Iron overload is especially a problem in refractory anaemias associated with hyperplastic bone marrow (e.g. thalassaemia major - in this condition inappropriate iron therapy and excessive iron absorption from the gut may add to iron overload)
  • desferroixamine may also be used in haemochromatosis where venesection is contraindicated
  • iron excretion mediated via administration of desferrioxamine is enhanced via administration of vitamin C

The summary of product characteristics should be consulted before prescribing this drug.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.